Who we are
What we do
Mucosis Announces Re-issue of Major Patent by US Patent Office – USPTO – for Prevention of Respiratory Syncytial Virus
July 2, 2019
SynGEM publication paper of the month on ReSViNET
April 5, 2019
First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of Inducing Long-Lasting Immune Responses
March 6, 2019
New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV challenge study.
February 27, 2019
Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV) show persistent antibody responses in humans.
February 13, 2019
Virtuvax to attend DCVMN in Kunming
September 19, 2018
Virtuvax for collaboration on your innovation in vaccine development or your biosimilar
May 12, 2017
Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?
February 14, 2017
Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”
Meet Virtuvax @ BioWin Day 2016
November 30, 2016
Ernst Soethout, MD
Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F vaccine technology. If you are interested, I would be most interested to meet you at the developing countries vaccine manufacturers network (DCVMN) annual meeting in Kunming, China, from October 29 - 31 2018.
Tags: vaccine development, disruptive technology, biosimilar, monoclonal antibody, vaccine technology, DCVMN, Kunming, vaccine consultancy, RSV, pre-fusion RSV-F, RSV vaccine, pneumococcal vaccine
Enterprise Europe Network
Life Science & Health